BIA
- Generic Name
- BIA
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20F3N3O5
- Unique Ingredient Identifier
- X6H65DT067
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2023-04-19
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Bial R&D Investments, S.A.
- Target Recruit Count
- 237
- Registration Number
- NCT05819359
- Locations
- 🇺🇸
Cedars-Sinai, Los Angeles, California, United States
🇺🇸University of Maryland Medical Center, Baltimore, Maryland, United States
🇺🇸Parkinson's Disease and Movement Disorders Cente at University of Pennyslvania, Philadelphia, Pennsylvania, United States
Effect of BIA 5-1058 400 mg on Warfarin Pharmacokinetics
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 26
- Registration Number
- NCT04994119
- Locations
- 🇩🇪
PAREXEL International - Early Phase Clinical Unit - Berlin, Berlin, Germany
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Sildenafil
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 20
- Registration Number
- NCT04994860
- Locations
- 🇩🇪
PAREXEL International - Early Phase Clinical Unit - Berlin, Berlin, Germany
Effect of Food on BIA 5-1058
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 57
- Registration Number
- NCT04991155
Effect of Age-gender on the Pharmacokinetic and Pharmacodynamic Profiles of BIA 5 1058
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 61
- Registration Number
- NCT04991194
Effect of BIA 5-1058 400 mg on the Steady State Pharmacokinetics of Bosentan
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2021-08-05
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 44
- Registration Number
- NCT04991207
- Locations
- 🇩🇪
PAREXEL International - Early Phase Clinical Unit - Berlin, Berlin, Germany
Effect of BIA 5-1058 on the Steady State Pharmacokinetics of Treprostinil
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 20
- Registration Number
- NCT04675944
- Locations
- 🇩🇪
PAREXEL International - Early Phase Clinical Unit, Berlin, Germany
Relative Bioavailability and Bioequivalence of Opicapone
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 45
- Registration Number
- NCT03820037
- Locations
- 🇬🇧
Covance Clinical Research, Leeds, United Kingdom
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIA 5-1058
- Conditions
- Pulmonary Arterial HypertensionCardiovascular Disease+Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 157
- Registration Number
- NCT03708146
- Locations
- 🇬🇧
Quotient Sciences, Ruddington, Nottingham, United Kingdom
Effect of BIA 5 1058 on Cardiac Repolarization
- Conditions
- Cardiovascular DiseasePulmonary Arterial HypertensionHeart Failure
- Interventions
- First Posted Date
- 2018-04-05
- Last Posted Date
- 2020-12-31
- Lead Sponsor
- Bial - Portela C S.A.
- Target Recruit Count
- 49
- Registration Number
- NCT03489005
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd., Leeds, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.